Alnylam Pharmaceuticals announced this week that its partner Genzyme has exercised an option to buy 344,448 unregistered shares of Alnylam stock for $23 million as part of the companies broad genetic diseases alliance disclosed earlier this year.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now. Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.
A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.
As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.
The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.
This webinar will discuss potential clinical applications for miRNA signatures and a novel, extraction-free miRNA profiling technology for advancing biomarker discovery.